Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
20 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

High medication nonadherence rate, elevated CVD risk after breast cancer diagnosis

Roshini Claire Anthony
27 Dec 2018

Women diagnosed with nonmetastatic breast cancer who were adherent to cardiovascular disease (CVD) medications pre-diagnosis had a high risk of becoming nonadherent post-cancer treatment, with nonadherence increasing their risk of CV events, according to a poster presented at the recent San Antonio Breast Cancer Symposium (SABCS 2018).

Researchers used data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database to identify 23,080 women with nonmetastatic (stage 1–3) breast cancer diagnosed between 2008 and 2013, of whom 67 percent (n=15,576) were adherent to one or more CVD medications prior to diagnosis. Adherence to medications (80 percent medication possession ratio) was assessed 1 year prior and 1–2 years after breast cancer diagnosis.

A total of 2,732 women (17.5 percent) were nonadherent to at least one CVD medication after breast cancer treatment.

Among those who were adherent to CVD medications before diagnosis, 19.2 percent were nonadherent to antihypertensives, 26.2 percent nonadherent to lipid-lowering medications, and 30.7 percent nonadherent to diabetes medications after 1 year of treatment for breast cancer. [SABCS 2018, abstract PD6-10]

Factors that affected the risk of nonadherence to antihypertensives were older age (hazard ratio [HR], 1.15; p=0.04 for age 80 vs 65–69 years), increasing comorbidities (HR, 1.34; p<0.0001 for Charlson score 1 vs 0), more advanced disease (HR, 1.18; p=0.0005 for stage 2–3 vs 1), and hormone receptor-negative status (HR, 1.15; p=0.04 vs hormone receptor-positive status).

Factors that increased the risk of nonadherence to lipid-lowering medications were increasing comorbidities (HR, 1.26; p<0.0001), more advanced disease (HR, 1.11; p=0.05), and hormone receptor-negative status (HR, 1.18; p=0.03), while only more advanced disease (HR, 1.19; p=0.007) and hormone receptor-negative status (HR, 1.23; p=0.02) increased nonadherence to diabetes medications.

Medication nonadherence after cancer treatment increased the risk of CVD events in women who had been adherent pre-treatment with elevated risks of hypertension (HR, 1.33; p<0.0001), hyperlipidaemia (HR, 1.21; p=0.009), and diabetes (HR, 1.31; p=0.003).

The cumulative 5-year incidence rate of CVD was also higher among patients who were nonadherent compared with those who were adherent to their CVD medications (34.20 percent vs 26.68 percent for antihypertensives, 30.56 percent vs 25.69 percent for lipid-lowering medications, and 33.07 percent vs 26.15 percent for diabetes medications; p<0.01 for all comparisons).

“Studies [have] shown that patients diagnosed with early-stage breast cancer are more likely to die from CVD than breast cancer,” said the researchers.

“[This study showed that] a large proportion of women who were previously adherent to their medications to prevent CVD events prior to their breast cancer diagnosis were nonadherent following treatment [with] nonadherence to CVD medications associated with an increased risk of a subsequent cardiac event,” they said.

“Improving outcomes and reducing morbidity following a breast cancer diagnosis also requires focused attention on non-breast cancer conditions. As breast cancer survival improves, physicians should pay particular attention to addressing CVD risk factors and medication adherence,” they suggested. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
20 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.